France Diabetes Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.30 Billion |
| Market Size (2029) | USD 1.79 Billion |
| CAGR (2024 - 2029) | 6.58 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
France Diabetes Devices Market Analysis
The France Diabetes Devices Market size is estimated at USD 1.30 billion in 2024, and is expected to reach USD 1.79 billion by 2029, growing at a CAGR of 6.58% during the forecast period (2024-2029).
In France, the prevalence of treated diabetes has been estimated at 4.6%, or more than 3 million people, and 5.2% in Northern France. The healthcare need for the treatment and management of diabetes is the main focus of the diabetes market. In France, the diabetes market is divided into self-monitoring of blood glucose (SBMG), continuous glucose monitoring (CGM), and insulin pumps. A survey conducted by the EU Commission revealed that one in 10 people in France has diabetes.
However, France does not have the highest diabetes prevalence rate in Europe. In 2022, Germany had the highest percentage of adults living with diabetes at 15.4%. Portugal followed with the second-highest rate at 14.6%. On the other hand, Ireland had the lowest diabetes rate in Europe at 4.5%. Still, nearly a million people are diagnosed with diabetes in France, according to the World Health Organization (WHO). And diabetes has the highest prevalence among all chronic conditions in France.
Diabetes has the highest prevalence among all chronic conditions covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region.
According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people.
Furthermore, approximately 0.26 million are estimated to live with Type 1 diabetes in the region. Thus, the rising prevalence of diabetes and obesity, growing awareness, regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes care devices in France.
In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applies to all of the countries. For diabetes technological devices in France, the reimbursement is based on the tariff system.
France Diabetes Devices Market Trends
Monitoring Devices Hold Highest Market Share in France Diabetes Care Devices Market
In France, over a lifetime time horizon, the G6 RT-CGM system is likely to be cost-effective compared with SMBG for individuals with long-standing T1D. One of the commitments stipulated in the French National Health Strategy for 2018-2022 was to guarantee prompt and universal access to innovations such as new medical devices.
However, there are increasing financial strains on many health systems, so a sizable clinical benefit that outweighs currently available technologies should be enough to justify the cost of novel technologies. Given the incremental clinical and QoL benefits afforded by the Dexcom G6 RT-CGM system in France. As people suffering from diabetes were at an increased risk of COVID-19 infection, the French companies ensured an adequate supply of the required monitoring devices on the market to ensure the well-being of the affected citizens.
In France, the insurance plans reduce the burden on the diabetic population. However, different policies exist for both the type-1 and type-2 diabetic populations. For instance, the insurance covers up to 200-400 test strips in a year for the type-2 population, whereas for the type-1 population, it covers approximately 3,000 test strips in a year.
Increasing Diabetes Population in France Boosting the France Diabetes Devices Market during forecasting period
In France, the type-1 diabetes population increased with a CAGR greater than 3% over the forecast period.
France is one of the 59 nations in the IDF-EUR area. Moreover, in 2022, 62 million individuals in the Europe Region and 538 million people worldwide were expected to have diabetes; by 2045, this number is expected to increase to 69 million. According to a survey by the EU Commission, the number of people in France who have chronic diabetes is the highest, and one in 10 people in France suffer from diabetes.
The prevalence of diabetes is significant in France, although the rules' target of 80% compliance with advised healthcare consultations isn't always met. To promote proactive therapy adjustment and decrease therapeutic inertia, new techniques that focus on patient and physician education and information are necessary to lessen the burden of complications and hospitalizations associated with diabetes.
According to a 2022 article titled "Epidemiology and Health Impact of Diabetes in France," problems associated with diabetes were more common in people with diabetes type-1 than type-2 over a 5-year period (52.2 vs. 34.7%). Over a period of two years, diabetes-related admissions were also more common in diabetes type-1 patients than in diabetes type-2 patients (29.8% vs. 16.9%).
When risk factors, including obesity and a sedentary lifestyle, continue to rise in France and elsewhere, it is challenging to reverse the diabetes trend there. In order to lessen the burden of the condition, the French public health law was modified in 2022 to add two provisions that aimed to boost adherence to the advised medical monitoring of diabetes patients and reduce the incidence of complications from diabetes, with a focus on cardiovascular events.
The French health authority (HAS) developed the recommended treatment routes for patients with DT1 and DT2, putting a focus on problem detection and cardiovascular risk monitoring. Despite these initiatives, the French diabetic population has struggled to accept the recommendations due to inertia.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in France.
France Diabetes Devices Industry Overview
The new technologies in diabetes devices, like continuous glucose monitoring, have increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring device market.
France Diabetes Devices Market Leaders
-
Dexcom
-
Abbott
-
Roche
-
Novo Nordisk
-
Medtronic
*Disclaimer: Major Players sorted in no particular order
France Diabetes Devices Market News
- September 2023: Dexcom has revealed that their Dexcom ONE system, which offers real-time continuous glucose monitoring (CGM), is now accessible in France for individuals with diabetes. This advancement in diabetes technology accessibility is a significant victory for those with diabetes, as it will extend this life-saving technology to an additional half a million individuals with diabetes in France.
- April 2022: CamDiab and Ypsomed announced the partnership to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of diabetes management for people with diabetes in European countries. The new integrated AID system is designed to connect Abbott's FreeStyle Libre 3 sensor, the world's smallest and most accurate continuous glucose monitoring sensor, to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump creating a smart, automated process to deliver insulin based on real-time glucose data.
France Diabetes Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Monitoring Devices
- 5.1.1 Self-monitoring Blood Glucose Devices
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Test Strips
- 5.1.1.3 Lancets
- 5.1.2 Continuous Blood Glucose Monitoring
- 5.1.2.1 Sensors
- 5.1.2.2 Durables
-
5.2 Management Devices
- 5.2.1 Insulin Pump
- 5.2.1.1 Insulin Pump Device
- 5.2.1.2 Insulin Pump Reservoir
- 5.2.1.3 Infusion Set
- 5.2.2 Insulin Syringes
- 5.2.3 Insulin Cartridges
- 5.2.4 Disposable Pens
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Becton and Dickenson
- 7.1.2 Medtronic
- 7.1.3 Insulet
- 7.1.4 Tandem
- 7.1.5 Ypsomed
- 7.1.6 Novo Nordisk
- 7.1.7 Sanofi
- 7.1.8 Eli Lilly
- 7.1.9 Abbottt
- 7.1.10 Roche
- 7.1.11 Lifescan (Johnson &Johnson)
- 7.1.12 Dexcom
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityFrance Diabetes Devices Industry Segmentation
More user-friendly and unobtrusive devices are available, from improved insulin pumps to continuous glucose monitors (CGM) and blood glucose meters. The France diabetes device market comprises component management devices and monitoring devices. The report offers the value (in USD) and volume (in units) for the above segments.
| Monitoring Devices | Self-monitoring Blood Glucose Devices | Glucometer Devices |
| Test Strips | ||
| Lancets | ||
| Monitoring Devices | Continuous Blood Glucose Monitoring | Sensors |
| Durables | ||
| Management Devices | Insulin Pump | Insulin Pump Device |
| Insulin Pump Reservoir | ||
| Infusion Set | ||
| Management Devices | Insulin Syringes | |
| Insulin Cartridges | ||
| Disposable Pens |
France Diabetes Devices Market Research FAQs
How big is the France Diabetes Devices Market?
The France Diabetes Devices Market size is expected to reach USD 1.30 billion in 2024 and grow at a CAGR of 6.58% to reach USD 1.79 billion by 2029.
What is the current France Diabetes Devices Market size?
In 2024, the France Diabetes Devices Market size is expected to reach USD 1.30 billion.
Who are the key players in France Diabetes Devices Market?
Dexcom, Abbott, Roche, Novo Nordisk and Medtronic are the major companies operating in the France Diabetes Devices Market.
What years does this France Diabetes Devices Market cover, and what was the market size in 2023?
In 2023, the France Diabetes Devices Market size was estimated at USD 1.21 billion. The report covers the France Diabetes Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the France Diabetes Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
France Diabetes Devices Industry Report
Statistics for the 2024 France Diabetes Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. France Diabetes Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
